Some promising currently available treatments for NMO include B-cell depletion (rituximab, inebilizumab), interleukin-6 signaling blockade (tocilizumab, satralizumab), and complement inhibition (eculizumab)4,6. This evidence concerns the gene IL6 and neuromyelitis optica.